Physician profile
Jonathan Mills
NPI 1558775130
$26,305.35
in general payments reported to CMS, 2019-2025
17 companies · $698 in 2025
The $698 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $77.15 · 2021: $188 · 2022: $636 · 2023: $577 · 2024: $699 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23,389.29 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,075.20 | 2020-2025 | |
| Abbvie INC. | $1,007.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $206.29 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $129.83 | 2022-2024 | Tremfya |
| Ucb, INC. | $117.13 | 2022-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $101.81 | 2025 | |
| Mallinckrodt Hospital Products INC. | $54.72 | 2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $54.36 | 2023-2025 | Saphnelo |
| Sanofi-Aventis U.S. LLC | $31.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.86 | 2023 | Cyltezo |
| Kiniksa Pharmaceuticals International, Plc | $25.51 | 2024 | Arcalyst |
| Lilly USA, LLC | $19.79 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $17.94 | 2023 | Arcalyst |
| Genentech USA, INC. | $17.22 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $16.01 | 2021 | |
| Kyowa Kirin, INC. | $14.48 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.